Drug intelligence / Profile preview

atezolizumab + ipilimumab

Development stage: Phase 1
Lead developer: Bristol Myers Squibb
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Atezolizumab + ipilimumab is an investigational drug combination of two immune checkpoint inhibitor monoclonal antibodies: atezolizumab, an anti–PD-L1 antibody, and ipilimumab, an anti–CTLA-4 antibody. Both agents work by potentiating T-cell mediated immune responses against cancer cells, but via different immune checkpoints—inhibiting PD-L1 and CTLA-4 respectively. This combination is being explored to enhance antitumor immune activity beyond what is achieved with either agent alone. Trials have focused on advanced solid tumors, including renal cell carcinoma and melanoma[4][1].

Other names: atezolizumab + ipilimumab

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on atezolizumab + ipilimumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on atezolizumab + ipilimumab.